Applicability of Histoculture Drug Response Assays in Colorectal Cancer Chemotherapy

The present study, using the histoculture drug response assay (HDRA) compared chemosensitivity with the clinical response of a treatment regime in patients with advanced colorectal cancer (CRC). A total of 324 patients with primary CRC were prospectively enrolled. HDRAs were performed using seven co...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Anticancer research 2012-08, Vol.32 (8), p.3581-3586
Hauptverfasser:	YOON, Yongsik, CHANWOOKKIM, SEONAEROH, HYUNGCHO, Dong, GYUPYOKIM, YONG SANG HONG, TAE WON KIM, MOON BO KIM, JIN CHEON KIM
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Colorectal Neoplasms - drug therapy Drug Screening Assays, Antitumor Female Gastroenterology. Liver. Pancreas. Abdomen Humans Male Medical sciences Middle Aged Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Tumor Cells, Cultured Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present study, using the histoculture drug response assay (HDRA) compared chemosensitivity with the clinical response of a treatment regime in patients with advanced colorectal cancer (CRC). A total of 324 patients with primary CRC were prospectively enrolled. HDRAs were performed using seven combinations of anticancer drugs, including 5-fluorouracil with leucovorin (FL), FL with oxaliplatin (FOLFOX), irinotecan (FOLFIRI), and their combinations with bevacizumab and cetuximab. Among 324 HDRA results, tumor inhibition rates of regimes using FOLFOX (34.2-39.2%) were higher than those using FOLFIRI (24.2-32.7%, p
ISSN:	0250-7005 1791-7530